Clinical Trials Logo

Clinical Trial Summary

This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To compare the rate of ctDNA clearance in "ctDNA detected" patients treated with or without adjuvant chemotherapy following resection of stage IIA colon cancer. (Phase II) II. To compare recurrence-free survival (RFS) in "ctDNA detected" patients treated with or without adjuvant chemotherapy following resection of stage IIA colon cancer. (Phase III) SECONDARY OBJECTIVES: I. To describe the prevalence of detectable ctDNA in patients with stage IIA colon cancer following surgical resection. II. To estimate time-to-event outcomes (overall survival [OS], recurrence-free survival [RFS], and time to recurrence [TTR]) by ctDNA marker status and treatment for patients with resected stage IIA colon cancer. III. To estimate the rate of compliance with adjuvant chemotherapy and/or active surveillance for patients with resected stage IIA colon cancer. EXPLORATORY OBJECTIVES: I. To describe the association of quantitative ctDNA levels with time to event outcomes (RFS, OS, and TTR). II. To characterize genomic profiles associated with recurrence using a ctDNA assay in patients with resected stage IIA colon cancer. III. To model the cost effectiveness of the use of ctDNA versus standard of care in this setting. IV. To evaluate performance of a ctDNA assay after incorporation of patient tumor and peripheral blood mononuclear cells. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I (BLOOD STORED AND TESTED FOR ctDNA LATER): Patients undergo active surveillance. ARM II (BLOOD TESTED FOR ctDNA AT BASELINE): Patients are assigned to 1 of 2 groups. GROUP I (ctDNA DETECTED): At the discretion of the investigator, patients receive either oxaliplatin intravenously (IV) over 2 hours on day 1, leucovorin IV over 2 hours on day 1, and fluorouracil IV bolus over 2-4 minutes on day 1 and then by continuous IV over 46-48 hours repeated every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or oxaliplatin IV over 2 hours on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14 repeated every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. GROUP II (ctDNA NOT DETECTED): Patients undergo active surveillance. After completion of study treatment, patients are followed up at 12 months and then every 6 months for 2 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04068103
Study type Interventional
Source NRG Oncology
Contact
Status Active, not recruiting
Phase Phase 2/Phase 3
Start date December 16, 2019
Completion date April 30, 2027

See also
  Status Clinical Trial Phase
Completed NCT04003181 - The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon N/A
Active, not recruiting NCT04057274 - Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth N/A
Completed NCT02127359 - Whole-Exome Sequencing (WES) of Cancer Patients
Completed NCT00096278 - Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer Phase 3
Active, not recruiting NCT02912559 - Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair Phase 3
Completed NCT02569723 - Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy N/A
Recruiting NCT05746195 - Optimization of Adaptive Text Messages for Cancer Survivors (OATS II) N/A
Active, not recruiting NCT03365882 - S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery Phase 2
Completed NCT02393755 - Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05710406 - Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer Phase 2/Phase 3
Recruiting NCT06017141 - Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study Phase 2
Active, not recruiting NCT03436563 - M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Phase 1/Phase 2
Recruiting NCT05482516 - Evaluating Novel Therapies in ctDNA Positive GI Cancers Phase 3
Completed NCT02368886 - Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer Phase 2
Active, not recruiting NCT02863107 - Young-Onset Colorectal Cancer
Active, not recruiting NCT04963283 - Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer Phase 2
Recruiting NCT06414304 - Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy
Completed NCT05872334 - The Safety and Feasibility of MONOFIX on Fascial Closure of Mid-line Wound After Minimally Invasive Colorectal Cancer Surgery N/A
Not yet recruiting NCT06426927 - PeLear CCC: Proyecto Latino Contra Cancer Colorectal N/A
Completed NCT03949777 - Validation of Aer-O-Scope Colonoscope System Cecal Intubation N/A